High-sensitivity troponin tests for the early rule out of NSTEMI

Introduction

Published date: September 2019 Last major update: August 2020. See update information for a summary of the changes.

This adoption resource has been compiled by the NICE adoption and impact team working with Roche Diagnostics Limited for the Accelerated Access Collaborative (AAC). It has been developed to provide practical information and advice to sites (NHS organisations) on adopting high-sensitivity troponin tests with early rule-out protocols. These would help to rule out non‑ST‑segment‑elevation myocardial infarction (NSTEMI) quickly in people presenting to an emergency department with chest pain suspected to be caused by acute coronary syndrome.

The AAC is a unique partnership bringing together leaders from across the healthcare landscape. This includes government, NHS, industry and patient representatives. The AAC aims to drive the uptake and adoption of innovation within the health and care system by identifying and supporting the best new innovations that will be most promising for patients.

The AAC is supporting the rapid uptake of 7 high-potential technology areas with full evidence bases already within the system. These products will enable patients to access new treatments faster and improve patients' lives but are not currently available to everyone who could benefit.

One of the technology areas selected is high-sensitivity cardiac troponin testing for early rule out of NSTEMI. This adoption resource forms part of the overall AAC implementation toolkit for this workstream.

The information in this document is based on the experiences of healthcare professionals working in 5 trusts in England and input from the National External Quality Assurance Service cardiac markers scheme.